Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
References (18)
- et al.
Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study
Clin Ther
(1997) Switch therapy in community-acquired pneumonia
Diagn Microbiol Infect Dis
(1995)- et al.
Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
Am Rev Respir Dis
(1993) - et al.
Community-acquired pneumonia: An update
Clevel Clin J Med
(1996) - et al.
Community-acquired pneumonia
NEJM
(1995) - et al.
Influence of age on symptoms at presentation in patients with community-acquired pneumonia
Arch Intern Med
(1997) - et al.
Prospective study of epidemiology and prognostic factors in community-acquired pneumonia
Eur J Clin Microbiol Infect Dis
(1996) - et al.
Prognosis, outcomes of patients with community-acquired pneumonia. A meta-analysis
JAMA
(1996) - et al.
Community-acquired pneumonia in adults: Initial antibiotic therapy
Am Fam Phys
(1997)
There are more references available in the full text version of this article.
Cited by (52)
Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial aetiology
2023, International Journal of Antimicrobial AgentsMortality and clinical cure rates for pneumonia: a systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments
2022, Clinical Microbiology and InfectionCitation Excerpt :Bacteriostatic antimicrobial therapeutics included tigecycline, oxazolidinones, macrolides, sulphonamides, and tetracyclines (Table S3). Twenty-three trials included patients with community-acquired pneumonia who were admitted to the hospital [34,36–38,40–42,44,45,47,49,51,52,56,59–61,65,66,71–73,75], whereas 10 trials included patients with nosocomial pneumonia [43,46,48,50,53,54,56,57,59,62]. The remaining 10 studies reported in- and outpatients with acute bacterial pneumonia as lower respiratory infections [35,63,64,67–70,73,74,76].
Macrolides vs. quinolones for community-acquired pneumonia: Meta-analysis of randomized controlled trials
2013, Clinical Microbiology and InfectionCardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (IMMEDIAT study)
2006, Medecine et Maladies InfectieusesClarithromycin in 2003: Sustained efficacy and safety in an era of rising antibiotic resistance
2004, International Journal of Antimicrobial AgentsTelithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia
2003, Clinical Microbiology and Infection
Copyright © 1999 Published by Elsevier Inc.